Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, Small D, Burnett A, Levis M.

Blood. 2011 Mar 24;117(12):3286-93. doi: 10.1182/blood-2010-01-266742. Epub 2011 Jan 24.

2.

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M.

Blood. 2010 Feb 18;115(7):1425-32. doi: 10.1182/blood-2009-09-242859. Epub 2009 Dec 10.

3.

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

Kancha RK, Grundler R, Peschel C, Duyster J.

Exp Hematol. 2007 Oct;35(10):1522-6.

PMID:
17889720
4.

FLT3 kinase inhibitors in the management of acute myeloid leukemia.

Illmer T, Ehninger G.

Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S24-34. Review.

PMID:
18282363
5.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.

6.

FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Fathi AT, Chabner BA.

Oncologist. 2011;16(8):1162-74. doi: 10.1634/theoncologist.2011-0084. Epub 2011 Jul 17.

7.

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F.

Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Review.

PMID:
22614177
8.

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ, Rudek MA, Smith BD.

Leukemia. 2010 Aug;24(8):1437-44. doi: 10.1038/leu.2010.132. Epub 2010 Jun 10.

9.

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.

Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.

Leukemia. 2012 Jul;26(7):1462-70. doi: 10.1038/leu.2012.52. Epub 2012 Feb 22.

10.

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F.

Expert Opin Investig Drugs. 2014 Jul;23(7):943-54. doi: 10.1517/13543784.2014.911839. Epub 2014 Apr 21. Review.

11.

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1874-7. doi: 10.1016/j.bbmt.2011.07.011. Epub 2011 Jul 20.

12.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
13.

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE.

Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.

14.

A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.

Fesler MJ, Richart JM, Petruska PJ.

Leuk Res. 2010 Oct;34(10):e268-9. doi: 10.1016/j.leukres.2010.03.046. Epub 2010 Apr 24. No abstract available.

PMID:
20417967
15.

FLT3 inhibitors for the treatment of acute myeloid leukemia.

Wiernik PH.

Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444. Review.

PMID:
20733555
16.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

17.

Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.

Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, Hollenback D, Eksterowicz J, Liang L, Weidner M, Huard J, Wang X, Alba G, Orf J, Lo MC, Zhao S, Ngo R, Chen A, Liu L, Carlson T, Quéva C, McGee LR, Medina J, Kamb A, Wickramasinghe D, Dai K.

Mol Cancer Ther. 2014 Apr;13(4):880-9. doi: 10.1158/1535-7163.MCT-13-0858. Epub 2014 Feb 13.

18.

Lestaurtinib: a multi-targeted FLT3 inhibitor.

Fathi AT, Levis M.

Expert Rev Hematol. 2009 Feb;2(1):17-26. doi: 10.1586/17474086.2.1.17. Review.

PMID:
21082990
19.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J.

Cancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24.

20.

Emerging Flt3 kinase inhibitors in the treatment of leukaemia.

Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H.

Expert Opin Emerg Drugs. 2006 Mar;11(1):153-65. Review.

PMID:
16503833

Supplemental Content

Support Center